Ajanta Pharma Shares Surge 5% as US Generics Revenue Skyrockets 56% in Q4

Synopsis: Ajanta Pharma Limited saw its shares climb nearly 5% today, May 6, 2026, following a robust Q4 FY26 earnings report. The pharmaceutical major reported an 18.4% YoY increase in net profit, fueled by a massive 56% surge in its US generics business and steady growth across its Indian and African branded markets.

Ajanta Pharma Limited has delivered a prescription for growth in its latest regulatory filing. The company reported a consolidated net profit of Rs. 266.70 crore for the quarter ended March 31, 2026, marking an 18.4% increase compared to the same period last year. Revenue from operations witnessed an even sharper trajectory, rising 21.5% YoY to reach Rs. 1,421.64 crore.

The star performer of the quarter was the company’s US generics business, which saw revenues skyrocket by 56% YoY to Rs. 505 crore. Domestic operations remained a stable pillar, with the India branded business growing 9% to Rs. 404 crore. While the Asia business faced a 10% dip, strong momentum in Africa up 37% helped offset the regional slowdown.

Operationally, the company maintained a healthy EBITDA margin of 23%. Notably, the bottom line was slightly impacted by a mark-to-market forex loss of Rs. 42 crore; excluding this, the core EBITDA would have reflected a 26% growth. For the full fiscal year FY26, Ajanta Pharma’s performance remained stellar, with total revenue crossing the Rs. 5,400 crore mark and a full-year profit of Rs. 1,056 crore, up 14.7% from the previous year.

Investors cheered the healthy scorecard, pushing Ajanta Pharma’s stock up by 5% during Wednesday’s trading session. As of 10:33 AM IST, the stock was trading at Rs. 3,042.50, recovering sharply from its early morning lows. The stock opened at Rs. 2,958.10 and touched an intraday high of Rs. 3,048, reflecting strong buying conviction.

The company’s market capitalization currently stands at approximately Rs. 37,994 crore. The stock has been on a steady recovery path, delivering an 8.45% return over the last week, significantly outperforming the Nifty Pharma index. With a high delivery percentage of 53.18%, market participants appear to be taking long-term bets on the company’s ability to sustain its double-digit growth margins and its high Return on Capital Employed (ROCE) of 33%.

Company Overview

Ajanta Pharma Limited is a leading specialty pharmaceutical formulation company with a dominant presence in branded generic markets. Headquartered in Mumbai, the company operates state-of-the-art manufacturing facilities and R&D centers. It focuses on high-growth therapeutic segments, including cardiology, dermatology, ophthalmology, and pain management. With an expansive global footprint across India, Asia, Africa, and the United States, Ajanta Pharma is recognized for its first-to-market product launches and robust supply chain.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Ajanta Pharma Shares Surge 5% as US Generics Revenue Skyrockets 56% in Q4 appeared first on Trade Brains.